Canaccord Genuity Maintains a 'Buy' on Hologic (HOLX); Now Largest Pure-Play in Molecular Diagnostics With GPRO Acquisition
Tweet
Share
E-mailGet Alerts HOLX Hot Sheet
Price: $76.01 --0%
Rating Summary:
6 Buy, 28 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 6 | Down: 6 | New: 57
Rating Summary:
6 Buy, 28 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 6 | Down: 6 | New: 57
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on Hologic (NASDAQ: HOLX) price target of $24.00.
Analyst, Jason R. Mills, said, "We maintain our rating following news that HOLX is acquiring Gen-Probe (Nasdaq: GPRO), which gives HOLX the largest pure play in molecular diagnostics and, most importantly, a highly synergistic, faster-growing women’s’ health asset. We like the acquisition at first blush – namely synergies, and potential for cash flow accretion and growth augmentation. What’s more, we remain bullish about the growth potential of the Breath Health business – namely potential inflection point with 3D Tomo over the next 18-24 months. While this deal is a big bite for HOLX, which understandably raises some concern regarding integration/performance, we believe GPRO is a best-in-class asset that portends obvious synergies that could augment long-term FCF growth."
For an analyst ratings summary and ratings history on Hologic click here. For more ratings news on Hologic click here.
Shares of Hologic closed at $19.12 yesterday.
Analyst, Jason R. Mills, said, "We maintain our rating following news that HOLX is acquiring Gen-Probe (Nasdaq: GPRO), which gives HOLX the largest pure play in molecular diagnostics and, most importantly, a highly synergistic, faster-growing women’s’ health asset. We like the acquisition at first blush – namely synergies, and potential for cash flow accretion and growth augmentation. What’s more, we remain bullish about the growth potential of the Breath Health business – namely potential inflection point with 3D Tomo over the next 18-24 months. While this deal is a big bite for HOLX, which understandably raises some concern regarding integration/performance, we believe GPRO is a best-in-class asset that portends obvious synergies that could augment long-term FCF growth."
For an analyst ratings summary and ratings history on Hologic click here. For more ratings news on Hologic click here.
Shares of Hologic closed at $19.12 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Upgrades Lens Technology Co Ltd (300433:CH) to Buy
- Seaport Global Securities Starts Funko (FNKO) at Buy
- Credo Tech (CRDO) Reiterated at Buy by Stifel: Expected to Beat Estimates
Create E-mail Alert Related Categories
Analyst Comments, Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
